Condition: Prostatic Neoplasms, Castration-Resistant · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Arizona Clinical Trials | Chandler, Arizona, United States | Recruiting |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| MemorialCare Orange Coast Medical Center | Fountain Valley, California, United States | Recruiting |
| University Of California San Diego | La Jolla, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Kaiser Permanente Southern California | Riverside, California, United States | Recruiting |
| Sharp Center for Research | San Diego, California, United States | Recruiting |
| Providence Saint John s Health Center | Santa Monica, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | Recruiting |
| Grand Valley Oncology | Grand Junction, Colorado, United States | Recruiting |
| Colorado Clinical Research | Lakewood, Colorado, United States | Recruiting |
+ 124 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07225946